

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

ETAS ID: TM506493

| | | | |
|---|-------------------------------------|-----------------------|-------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | | |
| NATURE OF CONVEYANCE: | SECURITY INTEREST | | |
| CONVEYING PARTY DATA | | | |
| Name | Formerly | Execution Date | Entity Type |
| MCGOWAN ENTERPRISES, INC. | | 01/18/2019 | Corporation: CALIFORNIA |
| RECEIVING PARTY DATA | | | |
| Name: | NXT CAPITAL, LLC, AS AGENT | | |
| Street Address: | 191 N. WACKER DRIVE | | |
| Internal Address: | 30TH FLOOR | | |
| City: | CHICAGO | | |
| State/Country: | ILLINOIS | | |
| Postal Code: | 60606 | | |
| Entity Type: | Limited Liability Company: DELAWARE | | |
| PROPERTY NUMBERS Total: 6 | | | |
| Property Type | Number | Word Mark | |
| Registration Number: | 5529237 | PHARMA-HOL | |
| Registration Number: | 4716371 | PHARMA-MAT | |
| Registration Number: | 4839561 | PHARMA-COAT | |
| Registration Number: | 4538877 | PHARMA-SURFACE GUARD | |
| Registration Number: | 4548434 | REVIVE WIPE | |
| Serial Number: | 87725249 | PHARMA-SAT | |
| CORRESPONDENCE DATA | | | |
| Fax Number: | 3129021061 | | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | | | |
| Phone: | 312-577-8208 | | |
| Email: | alana.hernandez@kattenlaw.com | | |
| Correspondent Name: | ALANA HERNANDEZ C/O KATTEN MUCHIN | | |
| Address Line 1: | 525 W MONROE STREET | | |
| Address Line 4: | CHICAGO, ILLINOIS 60661 | | |
| NAME OF SUBMITTER: | ALANA HERNANDEZ | | |
| SIGNATURE: | /ALANA HERNANDEZ/ | | |
| DATE SIGNED: | 01/18/2019 | | |

CH \$165.00 5529237

Total Attachments: 4

source=Trademark Security Agreement#page1.tif

source=Trademark Security Agreement#page2.tif

source=Trademark Security Agreement#page3.tif

source=Trademark Security Agreement#page4.tif

TRADEMARK SECURITY AGREEMENT

THIS TRADEMARK SECURITY AGREEMENT (the “**Agreement**”) made as of this 18th day of January, 2019, by McGowan Enterprises, Inc., a California corporation (“**Grantor**”), in favor of NXT Capital, LLC, in its capacity as Agent for the Lenders party to the Credit Agreement (defined below) (herein, “**Grantee**”):

WITNESSETH

WHEREAS, Grantor, one or more of its affiliates, Grantee and the lenders identified therein are parties to that certain Credit Agreement dated as of March 27, 2018 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “**Credit Agreement**”) providing for the extensions of credit to be made to Grantor (or one or more affiliates thereof) by Grantee and Lenders;

WHEREAS, pursuant to the terms of that certain Guarantee and Collateral Agreement dated as of March 27, 2018, among Grantor, one or more of its affiliates and Grantee (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “**Collateral Agreement**”), Grantor has granted to Grantee, for the benefit of Secured Parties, a security interest in substantially all of the assets of Grantor including all right, title and interest of Grantor in, to and under all now owned and hereafter acquired Trademarks (as defined in the Collateral Agreement), together with the goodwill of the business symbolized by Grantor’s Trademarks, and all products and proceeds thereof, to secure payment and performance of the Obligations;

NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Grantor agrees as follows:

1. Incorporation of Collateral Agreement. The Collateral Agreement and the terms and provisions thereof are hereby incorporated herein in their entirety by this reference thereto. All terms capitalized but not otherwise defined herein shall have the same meanings herein as in the Collateral Agreement.

2. Grant and Reaffirmation of Grant of Security Interests. To secure payment and performance of the Obligations, Grantor hereby grants to Grantee, for the benefit of Secured Parties, and hereby reaffirms its prior grant pursuant to the Collateral Agreement of, a continuing security interest in Grantor’s entire right, title and interest in and to the following (other than Excluded Property) (all of the following items or types of property being herein collectively referred to as the “**Trademark Collateral**”), whether now owned or existing or hereafter created, acquired or arising:


(i) each Trademark listed on Schedule 1 annexed hereto, together with any reissues, continuations or extensions thereof, and all of the goodwill of the business connected with the use of, and symbolized by, each Trademark; and

(ii) all products and proceeds of the forgoing, including without limitation, any claim by Grantor against third parties for past, present or future (a) infringement or dilution of any Trademark, or (b) injury to the goodwill associated with any Trademark.

[Signature Page Follows]

IN WITNESS WHEREOF, Grantor has duly executed this Agreement as of the date first written above.

MCGOWAN ENTERPRISES, INC., a
California corporation

By: 
Name: Patrick Fitzmaurice
Title: Chief Financial Officer and Vice President

Agreed and Accepted
As of the Date First Written Above:

NXT CAPITAL, LLC, as Agent

By: 

Name: Andrew Ippolite

Title: Director

SCHEDULE 1

Trademark Registrations

| Trademark | Registration Number | Registration Date | Jurisdiction |
|----------------------|----------------------------|--------------------------|---------------------|
| PHARMA-HOL | 5529237 | 7/31/2018 | USPTO |
| PHARMA-MAT | 4716371 | 4/7/2015 | USPTO |
| PHARMA-COAT | 4839561 | 10/27/2015 | USPTO |
| PHARMA-SURFACE GUARD | 4538877 | 5/27/2014 | USPTO |
| REVIVE WIPE | 4548434 | 6/10/2014 | USPTO |

Trademark Applications

| Trademark | Application Number | Application Date | Jurisdiction |
|------------------|---------------------------|-------------------------|---------------------|
| PHARMA-SAT | 87725249 | 12/18/2017 | USPTO |